Smith+Nephew 二季度收入不及预期并下调全年收入增长指引

BofA says this memory stock could double. Here are 5 reasons why
Introduction & Market Context
Smith+Nephew (NYSE:SNN) presented its second quarter and half-year 2026 results on August 4, revealing a complex performance picture that sent shares down 4.7% in premarket trading to $30.64. While the medical device company delivered strong profit growth and margin expansion, underlying revenue growth of just 1.6% in Q2 fell short of Wall Street’s expectations, prompting management to lower full-year sales guidance while maintaining profit targets.
The presentation highlighted the company’s ability to drive profitability through operational efficiency, even as revenue growth slowed due to weakness in U.S. orthopaedics and advanced wound bioactives. At the premarket price, shares traded near the lower end of their 52-week range of $28.56 to $38.79, reflecting investor concerns about the company’s growth trajectory despite improved profitability metrics.
Executive Summary
As outlined in the company’s performance summary, Smith+Nephew’s Q2 2026 results reflected divergent trends across its business portfolio. The quarter saw underlying revenue growth of 1.6%, described by management as "lower than expected," with strength in Sports Medicine offset by softness in U.S. Orthopaedics and Advanced Wound Bioactives.
Despite the revenue headwinds, the company achieved H1 trading profit of $566 million, representing 8.1% year-over-year growth. This performance was driven by a significant step-up in efficiency savings and tariff refunds that fully offset forecast tariff headwinds. Excluding mergers and acquisitions, H1 trading profit growth reached 9.0%.
Management reduced its full-year revenue outlook to approximately 4.0% growth, down from earlier expectations, while maintaining guidance on all other metrics. The company identified an additional $50 million in savings for 2026, bringing total annual savings to approximately $200 million, which is expected to offset the impact of lower revenue growth.
Quarterly Performance Highlights
The company’s Q2 2026 revenue performance showed significant variation across business units and geographic regions, as illustrated in the detailed breakdown below.
Total Q2 revenue reached $1,597 million, with reported growth of 2.8% benefiting from a 120 basis point foreign exchange tailwind. The quarter had the same number of trading days as Q2 2025, eliminating calendar effects as a factor in the year-over-year comparison.
Sports Medicine & ENT delivered the strongest performance with 8.6% underlying growth, reaching $527 million in revenue. This was driven by robust demand for key products including REGENETEN®, Q-FIX KNOTLESS®, and FASTSEAL®, with all regions contributing to growth.
Advanced Wound Management revenue of $456 million declined 2.1% on an underlying basis, impacted by U.S. reimbursement changes affecting skin substitutes and softer SANTYL® performance following a strong prior quarter.
Orthopaedics revenue of $614 million fell 1.0%, with weakness concentrated in U.S. knees (down 7.2%) and U.S. hips (down 1.5%). The knee decline, while significant, showed sequential improvement driven by strong uptake of LEGION® MS. Management attributed the hip weakness to delays in CATALYSTEM® set deployments rather than broader market issues.
Geographically, the U.S. market declined 1.3% to $816 million, while emerging markets demonstrated resilience with 10.6% growth to $292 million. Other established markets grew 1.7% to $489 million.
Detailed Financial Analysis
For the first half of 2026, Smith+Nephew’s financial performance showed improving profitability metrics despite modest revenue growth. The waterfall chart below illustrates the progression from H1 2025 to H1 2026 revenue.
Total H1 revenue reached $3,097 million, up 4.6% on a reported basis and 2.3% on an underlying basis. Sports Medicine & ENT contributed $72 million in incremental revenue, while Orthopaedics and Advanced Wound Management were essentially flat year-over-year. A $67 million translational foreign exchange impact provided additional reported growth.
The company’s H1 trading income statement demonstrated strong margin expansion despite the modest revenue growth.
Gross profit reached $2,203 million with a margin of 71.1%, up 60 basis points from 70.5% in H1 2025. This improvement reflected efficiency gains in manufacturing and procurement, as well as favorable product mix. Trading profit of $566 million represented an 18.3% margin, up from 17.7% in the prior year period.
Selling, general and administrative expenses increased 4.7% to $1,487 million, while research and development spending rose 5.0% to $150 million, indicating continued investment in growth initiatives even as the company pursued cost savings.
Adjusted earnings per share reached 47.7 cents, up 11.0% year-over-year, outpacing trading profit growth due to the benefit of share buybacks that reduced the weighted average share count. The company increased its interim dividend 4.0% to 15.6 cents per share, maintaining its track record of 50 consecutive years of dividend payments.
Profitability and Efficiency Initiatives
A key theme throughout the presentation was Smith+Nephew’s success in driving profitability through operational efficiency, even as revenue growth disappointed. The waterfall chart below illustrates the various factors influencing H1 trading profit growth.
The company faced significant headwinds totaling $152 million, including $56 million in cost inflation, $33 million in growth investments, $38 million in inventory revaluation, $18 million from Advanced Wound Management reimbursement changes, and $7 million from ENT volume-based procurement in China.
These headwinds were more than offset by positive drivers totaling $195 million, led by $128 million in efficiency savings and $59 million in operating leverage. Foreign exchange contributed $6 million, while tariffs had a net positive impact of $5 million due to refunds offsetting the tariff headwind.
The company’s multi-year savings program has delivered impressive cumulative results, as shown in the detailed breakdown of savings initiatives.
Annual savings reached $200 million in 2026 (estimated), with cumulative run-rate savings from the 12-Point Plan and Zero-Based Budgeting initiatives approaching $350 million. The largest savings contributions came from manufacturing and procurement, followed by sales and marketing, and business support functions.
Management emphasized that these savings are being achieved without compromising growth investments. Chief Financial Officer John Rogers stated in the earnings call, "We are not sort of strangling the business vis-a-vis growth. In fact, we’re very deliberately investing in growth in the business."
Trading margins improved across most business units, as illustrated in the segment-level performance data.
Sports Medicine & ENT trading margin expanded to 24.7% in H1 2026 from 23.1% in H1 2025, while Orthopaedics margin increased to 13.0% from 12.7%. Advanced Wound Management margin of 22.0% was essentially flat, impacted by the U.S. reimbursement headwind affecting skin substitutes.
The company also made significant progress on inventory management, with days sales inventory declining from 505 days in H1 2025 to 433 days in H1 2026 on a reported basis (465 days excluding the reclassification of instrument sets from inventory to property, plant and equipment).
Updated Guidance and Outlook
Despite reducing its revenue growth outlook, Smith+Nephew maintained guidance on all other key financial metrics for 2026, reflecting confidence in its ability to manage profitability through operational efficiency.
The company now expects approximately 4% underlying revenue growth for the full year 2026, down from earlier projections. However, it maintained guidance for approximately 8% trading profit growth (excluding M&A), trading profit of approximately $1.3 billion (including marginal Integrity Orthopaedics dilution), free cash flow of approximately $800 million, and return on invested capital above 10%.
Management expects a significant step-up in revenue growth during the second half of 2026, with H2 growth projected at 5.0-5.5% compared to H1’s 2.3%. The drivers of this anticipated acceleration are detailed in the company’s outlook presentation.
Key drivers for the H2 revenue step-up include continued momentum in Sports Medicine & ENT with strong growth in REGENETEN® and FASTSEAL®, stabilization of U.S. skin substitutes and return to growth in SANTYL® within Advanced Wound Management, and improving trajectory in U.S. knees driven by LEGION® MS alongside the launch of LANDMARK® and return to U.S. hips growth in Orthopaedics. An extra trading day in Q4 will also provide a modest tailwind.
Chief Executive Deepak Nath addressed concerns about the company’s medium-term growth target during the earnings call, stating, "The fundamental growth drivers, which are new products, either in existing categories or in creative new categories, those drivers remain well intact."
The full-year trading profit outlook remains supported by the waterfall of drivers and headwinds, with efficiency savings playing a crucial role in offsetting revenue-related pressure while maintaining investment in growth initiatives.
Strategic Initiatives
Smith+Nephew’s innovation pipeline remains central to its growth strategy, with the company showcasing a range of incremental and transformative products across its three business segments.
In Sports Medicine, key focus areas include driving increased market penetration of REGENETEN® for rotator cuff repair, capitalizing on the strength of the shoulder portfolio including the recently acquired Integrity Orthopaedics assets, and launching TESSA®, described as the industry’s first spatial surgery arthroscopic platform. TESSA received FDA approval in July 2026 with a limited launch planned for Q3.
Advanced Wound Management initiatives center on taking share with ALLEVYN COMPLETE CARE, which launched in the U.S. and Europe in H1 2026 with positive early feedback, navigating the CMS reimbursement change to skin substitutes, and accessing new care settings and patient populations with products including PICO and the LEAF Patient Monitoring System. The recently launched LEAF 3.0 represents the next generation of this technology.
In Orthopaedics, the company is focused on driving growth with the CORI® robotic platform, supported by the launch of shoulder execution capabilities. The first CORI XT cases on shoulders and knees were completed in H1 2026, with hip execution planned for H1 2027. The LANDMARK® knee system, addressing a critical portfolio gap in cementless knees, is scheduled for launch in Q3 2026 (cementless) and H1 2027 (cemented).
The company’s RISE strategy—Execute efficiently, Scale through strategic investment, Innovate to enhance standard of care, and Reach more patients—continues to guide operational priorities, with notable H1 achievements including the Suzhou manufacturing site receiving the Shingo Prize for organizational excellence and the acquisition of Integrity Orthopaedics to strengthen the shoulder portfolio.
Risks and Challenges
While Smith+Nephew’s presentation emphasized positive developments, the earnings call and market reaction highlighted several significant challenges facing the business.
U.S. orthopaedics weakness emerged as the primary concern, particularly in knees where the company lacks a cementless offering across part of its installed base. CEO Deepak Nath acknowledged, "The biggest factor are really company-specific factors. Fundamentally, it’s a knees," pointing to this portfolio gap as the main driver of the 7.2% decline in U.S. knee sales.
Advanced Wound Bioactives faced headwinds from prior authorization requirements from a payer affecting SANTYL® prescriptions, as well as continued pressure on skin substitutes from CMS reimbursement changes. While management expects stabilization and recovery in H2, the timing and magnitude of this improvement remain uncertain.
In Sports Medicine, the company anticipates softer performance in Q3 due to the implementation of volume-based procurement in China, which has already impacted ENT sales. The China VBP implementation, initially expected in H2, represents an ongoing headwind for the business.
Execution risk around new product launches remains significant, as the company’s growth acceleration depends heavily on successful commercialization of LANDMARK®, TESSA®, and other pipeline products. Any delays or slower-than-expected adoption could further pressure the revenue outlook.
Cash flow performance in H1, while positive at $231 million, declined from $244 million in the prior year period, primarily due to increased capital expenditure ($190 million vs. $139 million) and higher working capital needs. Trading cash conversion of 77% fell short of the 93% achieved in H1 2025, though management views this as a timing issue related to strategic investments.
The company’s net debt increased to $3,019 million from $2,759 million at year-end 2025, reflecting the Integrity Orthopaedics acquisition ($221 million), dividends ($205 million), and share buybacks ($116 million). The leverage ratio of 1.8x remains comfortable, but limits financial flexibility for additional large acquisitions in the near term.
Despite these challenges, management emphasized the underlying resilience of the business, pointing to consistent improvement in key operational metrics including trading profit margin, cumulative cost savings, inventory efficiency, and free cash flow generation over the past several years.
The presentation concluded with management’s assertion that Smith+Nephew has become "a more robust and resilient business, despite slower than expected revenue growth," supported by the sustained improvement in these key performance indicators from H1 2023 through H1 2026.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.